Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.
Momenta Pharmaceuticals, which is developing a biosimilar to Eylea (aflibercept) in collaboration with Mylan and collaborated with Sandoz on the Glatopa (glatiramer acetate) generic version of Teva’s Copaxone, is to be acquired by biotech major Johnson & Johnson for $52.50 a share.
The definitive agreement, which has been unanimously approved by the boards of directors of both Momenta and J&J and is...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
